SBI Securities Co. Ltd. Purchases Shares of 3,429 BioNTech SE (NASDAQ:BNTX)

SBI Securities Co. Ltd. purchased a new stake in BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,429 shares of the company’s stock, valued at approximately $391,000.

Other institutional investors have also recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its stake in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares during the period. Planning Capital Management Corp lifted its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the period. GAMMA Investing LLC lifted its stake in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the period. AlphaCentric Advisors LLC acquired a new position in shares of BioNTech in the 4th quarter valued at about $168,000. Finally, SVB Wealth LLC acquired a new position in shares of BioNTech in the 4th quarter valued at about $204,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX opened at $109.65 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a 50 day moving average price of $117.05 and a two-hundred day moving average price of $112.46. The firm has a market capitalization of $26.29 billion, a P/E ratio of -52.21 and a beta of 0.17. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BNTX. Wells Fargo & Company began coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Canaccord Genuity Group upped their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Finally, TD Cowen dropped their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.